Tag Archives: Dave Fredrickson

AstraZeneca: US FDA approval for Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer

Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo) CAMBRIDGE, 22-Feb-2018 — /EuropaWire/ — AstraZeneca and … Read the full press release

AstraZeneca: Japan approval for Lynparza (olaparib) tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release